rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Imunon, Inc.

IMNN · Nasdaq

Health CareBiotechnologyNot moving yet

IMNN stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 49.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$76K
Officials’ trades on record
0
Institutions holding
22 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$40K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months6
Buyers · sellers0 · 1
WhoDidSharesTraded
Susan EylwardGeneral Counsel and Corp Secsold2,525at $1.5631 Aug 2026filed 1 Sep 2026
Susan EylwardGeneral Counsel and Corp Secsold2,449at $1.6317 Aug 2026filed 17 Aug 2026
Susan EylwardGeneral Counsel and Corp Secsold2,541at $1.573 Aug 2026filed 4 Aug 2026
Susan EylwardGeneral Counsel and Corp Secsold2,150at $1.7820 Jul 2026filed 21 Jul 2026
Susan EylwardGeneral Counsel and Corp Secsold920at $1.886 Jul 2026filed 7 Jul 2026
Susan EylwardGeneral Counsel and Corp Secsold11,800at $1.7529 Jun 2026filed 29 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders22+5 on the quarter
New · exited6 · 1
Reported value$723K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
ARMISTICE CAPITAL, LLCreduced · filed 14 Aug 2026144,767$258K-203,563−58.4%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 202646,967$84K-1,089−2.3%
Riverview Capital Advisers, LLCunchanged · filed 13 Aug 202634,364$248K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202631,629$56K-1,582−4.8%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202613,269$24K00.0%
NORTHERN TRUST CORPnew · filed 13 Aug 202610,342$18K+10,342
UBS Group AGadded · filed 13 Aug 20265,203$9,261+4,628+804.9%
BlackRock, Inc.unchanged · filed 7 Aug 20264,464$7,94600.0%
Tower Research Capital LLC (TRC)added · filed 11 Aug 20263,952$7,035+2,086+111.8%
WELLS FARGO & COMPANYunchanged · filed 14 Aug 20263,342$5,94800.0%
31 Mar 2023 – 30 Jun 2026
152024Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Douglas Vincent Faller Company insiderChief Medical Officer · last 9 Oct 20260 · 0
Michael H. Tardugno Company insiderExecutive Chairman of Board · last 9 Oct 202632 · 0
Stacy Lindborg Company insiderPresident and CEO · last 9 Oct 20261 · 0
Susan Eylward Company insiderGeneral Counsel and Corp Sec · last 31 Aug 20260 · 6
Christine A. Pellizzari Company insiderDirector · last 31 Jul 20260 · 0
Donald P. Braun Company insiderDirector · last 31 Jul 20262 · 0
Frederick J. Fritz Company insiderDirector · last 31 Jul 202622 · 0
James E. Dentzer Company insiderDirector · last 31 Jul 20260 · 0
Khursheed Anwer Company insiderChief Scientific Officer · last 2 Jan 20260 · 0
Kimberly Bragg Company insiderCFO · last 2 Jan 20260 · 0
Jeffrey Wayne Church Company insiderCFO · last 15 Mar 20243 · 0
Sebastien Hazard Company insiderChief Medical Officer · last 7 Dec 20230 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-191%
Share count trendFY 2025 · to 30 Mar 202614.7%
Cash and equivalentsFY 2025 · to 31 Dec 2025$8.8M
Free cash flowFY 2025 · to 31 Dec 2025−$14.2M

Analyst forecasts

No analyst forecasts yet.